Alexion Pharmaceuticals, Inc. (ALXN) Expected to Announce Quarterly Sales of $876.57 Million
Wall Street analysts forecast that Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) will report sales of $876.57 million for the current quarter, Zacks reports. Nine analysts have made estimates for Alexion Pharmaceuticals’ earnings, with estimates ranging from $847.72 million to $900.89 million. Alexion Pharmaceuticals posted sales of $831.00 million during the same quarter last year, which would indicate a positive year over year growth rate of 5.5%. The company is scheduled to issue its next earnings report on Thursday, February 15th.
According to Zacks, analysts expect that Alexion Pharmaceuticals will report full-year sales of $876.57 million for the current year, with estimates ranging from $3.49 billion to $3.54 billion. For the next fiscal year, analysts forecast that the firm will report sales of $4.07 billion per share, with estimates ranging from $3.91 billion to $4.28 billion. Zacks’ sales calculations are an average based on a survey of research firms that cover Alexion Pharmaceuticals.
Alexion Pharmaceuticals (NASDAQ:ALXN) last announced its earnings results on Thursday, October 26th. The biopharmaceutical company reported $1.44 EPS for the quarter, beating the consensus estimate of $1.32 by $0.12. The business had revenue of $859.00 million for the quarter, compared to the consensus estimate of $864.34 million. Alexion Pharmaceuticals had a return on equity of 12.55% and a net margin of 14.57%. The company’s revenue was up 7.5% on a year-over-year basis. During the same period last year, the business posted $1.23 EPS.
Shares of Alexion Pharmaceuticals (NASDAQ ALXN) traded up $1.77 during trading hours on Tuesday, hitting $124.48. The company had a trading volume of 4,150,000 shares, compared to its average volume of 2,090,000. The stock has a market cap of $27,810.00, a P/E ratio of 55.57, a P/E/G ratio of 1.03 and a beta of 1.17. The company has a current ratio of 2.96, a quick ratio of 2.51 and a debt-to-equity ratio of 0.35. Alexion Pharmaceuticals has a 1-year low of $96.18 and a 1-year high of $149.34.
In other Alexion Pharmaceuticals news, CEO Ludwig Hantson sold 2,553 shares of the firm’s stock in a transaction that occurred on Tuesday, January 2nd. The stock was sold at an average price of $121.63, for a total transaction of $310,521.39. Following the completion of the sale, the chief executive officer now owns 36,172 shares in the company, valued at approximately $4,399,600.36. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 4.35% of the stock is owned by company insiders.
Hedge funds and other institutional investors have recently modified their holdings of the business. Jennison Associates LLC grew its stake in Alexion Pharmaceuticals by 720.0% during the 3rd quarter. Jennison Associates LLC now owns 5,332,636 shares of the biopharmaceutical company’s stock valued at $748,116,000 after purchasing an additional 4,682,336 shares in the last quarter. Assenagon Asset Management S.A. grew its position in shares of Alexion Pharmaceuticals by 4,509.0% in the 3rd quarter. Assenagon Asset Management S.A. now owns 884,150 shares of the biopharmaceutical company’s stock worth $124,037,000 after acquiring an additional 864,967 shares in the last quarter. USA Financial Portformulas Corp acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $3,632,000. IFC Holdings Incorporated FL acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $861,000. Finally, Chicago Equity Partners LLC acquired a new position in shares of Alexion Pharmaceuticals in the 3rd quarter worth approximately $320,000. Hedge funds and other institutional investors own 94.27% of the company’s stock.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.